Umifenovir in Hospitalized COVID-19 Patients

Summary

The present study is a randomized, double-blind, placebo-controlled, clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Loghman Hakim Medical Education Center in Tehran. Patients will be randomly assigned to the two arms of the study and after completing the course of treatment and collecting and analyzing the necessary information from each patient, the results of the study will be published both on this site and in the form of an article in a reputable international journal.

Conditions

• COVID-19

Interventions

DRUG

Umifenovir

This will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of Umifenovir in COVID-19 patients.

DRUG

Interferon-β 1a

This Drug will be used in all arms as we discovered its benefits in our previous randomized clinical trial.

DRUG

Lopinavir / Ritonavir

This Drug will be used in all arms as mandated by our governmental guidelines.

DRUG

Single Dose of Hydroxychloroquine

This Drug will be used in all arms as mandated by our governmental guidelines.

DRUG

Standards of Care

This Drug will be used in all arms as mandated by our governmental guidelines.

Sponsors & Collaborators

• Shahid Beheshti University of Medical Sciences

  lead OTHER

Principal Investigators

• Shervin Shokouhi, MD · Shahid Beheshti University of Medical Sciences

• Ilad Alavi Darazam, MD · Shahid Beheshti University of Medical Sciences

• Minoosh Shabani, MD · Shahid Beheshti University of Medical Sciences

• Mohammadreza Haji Esmaelie, MD · Shahid Beheshti University of Medical Sciences

• Latif Gachkar, MD · Shahid Beheshti University of Medical Sciences

• Mahdi Amirdosara, MD · Shahid Beheshti University of Medical Sciences

• Masoud Mardani, MD · Shahid Beheshti University of Medical Sciences

• Seyed Sina Naghibi Irvani, MD, MPH, MBA · Shahid Beheshti University of Medical Sciences

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-04-15

Primary Completion

2020-04-22

Completion

2020-04-24

Countries

• Iran

Study Locations